Company Overview - New Mile Health Technology Group Co., Ltd. focuses on medical services and pharmaceutical industry, with a primary product line that includes medicines and medical products [1] - The company has over 20 years of experience in drug production, establishing a series of traditional Chinese medicine centered around the "Duyiwei" brand, which is recognized in the 2020 edition of the "Chinese Pharmacopoeia" [1] Financial Performance - For Q1 2025, the company reported a revenue of 796 million yuan, a year-on-year decrease of 16.49%, and a net profit of 25.65 million yuan, down 9.35% year-on-year, with a gross margin of 27.96% [1] - The current stock price is 2.17 yuan, reflecting a decline of 1.36%, with a rolling price-to-earnings (PE) ratio of 65.56 times [1] Market Position - The average PE ratio for the medical services industry is 41.66 times, with a median of 43.26 times, positioning New Mile at 34th place within the industry [2] - The company's total market capitalization is 7.351 billion yuan [2] Shareholder Information - As of June 10, 2025, New Mile has 64,494 shareholders, an increase of 419 since the last report, with an average holding value of 352,800 yuan and an average holding quantity of 27,600 shares [1]

Core Insights - HomeFacialPro (hfp) has announced actress Liu Tao as its new spokesperson, promoting the theme "Gentle, Yet Powerful" to highlight the effectiveness of its fruit acid skincare products [1][2] - The collaboration aims to resonate with hfp's brand philosophy of "Let Ingredients Touch the Skin," emphasizing the importance of effective ingredients in skincare [2][4] Brand and Product Strategy - hfp focuses on addressing skincare issues such as excessive oil secretion and dull skin by utilizing fruit acid ingredients, specifically through its fruit acid essence water product [3][4] - The fruit acid essence water features a three-generation fruit acid formula that targets different skin layers, effectively unclogging pores and improving skin conditions like blackheads and acne [3] - The product includes innovative ingredients like bifida ferment and centella asiatica extract, ensuring a gentle yet effective skincare experience with a 90% repair essence base [3] Market Position and Performance - hfp has established a diverse product matrix, including various skincare items from basic lotions to advanced serums, accumulating over 30 million users [4] - The brand has been recognized as the top seller in the fruit acid skincare e-commerce market in China for three consecutive years, solidifying its position as the leading fruit acid facial care brand [4][5] - hfp's success is attributed to its deep understanding of user needs and strong research capabilities, including a partnership with Shanghai Jiao Tong University for innovative fruit acid research [4][6]

本公司及董事会全体成员保证公告内容真实、准确和完整，没有虚假记载、误导性陈述或者重大遗漏。 名称：康县独一味药材种植开发有限公司 一、担保情况概述 近日，新里程健康科技集团股份有限公司（以下简称"新里程"或"公司"）全资子公司康县独一味生物制 药有限公司（以下简称"独一味制药"）与兰州银行股份有限公司陇南武都支行（以下简称"兰州银行武 都支行"）分别签署了《最高额连带责任保证合同》，独一味制药分别为康县独一味药材种植开发有限 公司（以下简称"独一味种植"）、甘肃佛仁制药科技有限公司（以下简称"佛仁制药"）向兰州银行武都 支行申请最高授信额度提供连带责任保证，担保额度分别为人民币1,000万元及1,450万元。 二、担保审议情况 上述担保为全资子公司对公司合并报表范围内的子公司及二级控股子公司提供担保，均已履行了内部决 策程序，佛仁制药其他股东曹明月同时提供了相应的担保。根据《深圳证券交易所上市公司自律监管指 引第1号一一主板上市公司规范运作》的相关规定，无需提交公司董事会和股东大会审议。 三、被担保方基本情况 1、基本情况 成立日期：2011年11月8日 注册地点：甘肃省陇南市康县王坝独一味工业园区 法定代表 ...

新里程健康科技集团股份有限公司 证券简称：新里程 证券代码：002219 公告编号：2025-040 新里程健康科技集团股份有限公司 关于全资子公司为子公司及二级控股子公司提供担保的公告 本公司及董事会全体成员保证公告内容真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏。 一、担保情况概述 近日，新里程健康科技集团股份有限公司（以下简称"新里程"或"公司"） 全资子公司康县独一味生物制药有限公司（以下简称"独一味制药"）与兰州银 行股份有限公司陇南武都支行（以下简称"兰州银行武都支行"）分别签署了《最 高额连带责任保证合同》，独一味制药分别为康县独一味药材种植开发有限公司 （以下简称"独一味种植"）、甘肃佛仁制药科技有限公司（以下简称"佛仁制 药"）向兰州银行武都支行申请最高授信额度提供连带责任保证，担保额度分别 为人民币 1,000 万元及 1,450 万元。 二、担保审议情况 上述担保为全资子公司对公司合并报表范围内的子公司及二级控股子公司 提供担保，均已履行了内部决策程序，佛仁制药其他股东曹明月同时提供了相应 的担保。根据《深圳证券交易所上市公司自律监管指引第 1 号——主板上市公司 规范运作》 ...

Group 1 - The core viewpoint of the articles highlights the financial performance and market position of New Mile Health Technology Group Co., Ltd, indicating a decline in revenue and net profit in the latest quarterly report [1][2] - As of June 30, the closing price of New Mile was 2.2 yuan, down 1.79%, with a rolling PE ratio of 66.47 times and a total market value of 7.452 billion yuan [1] - The company operates in the medical services and pharmaceutical industry, focusing on drug production for over 20 years, with its main product being the "Duyiwei" series of traditional Chinese medicine [1] Group 2 - The average PE ratio for the medical services industry is 41.55 times, with a median of 42.46 times, positioning New Mile at 34th place among its peers [2] - The latest quarterly report for Q1 2025 shows that the company achieved a revenue of 796 million yuan, a year-on-year decrease of 16.49%, and a net profit of 25.65 million yuan, down 9.35% year-on-year, with a gross profit margin of 27.96% [1]

Group 1: Market Performance - The US stock market showed strong momentum on June 27, with all three major indices opening higher, marking a significant recovery from earlier declines [1] - The S&P 500 index successfully surpassed its historical high from February 2025, while the Nasdaq Composite index exceeded its December 2024 high, recovering from a 27% decline earlier this year [1] - Nvidia's stock performed exceptionally well, achieving over a 1% increase and reaching a new all-time high, with its market capitalization surpassing $3.8 trillion, reclaiming the title of the world's most valuable company [1] Group 2: Sector Performance - Technology stocks, particularly in the semiconductor and AI sectors, were the primary drivers of the market's upward movement [1] - The Philadelphia Semiconductor Index rose by 0.7%, with ARM's stock increasing by over 3% and Intel's stock rising by over 2%, further solidifying the leading position of tech stocks in the market [1] Group 3: Investment Outlook - UBS Wealth Management expressed optimism about the US stock market, raising its year-end target for the S&P 500 index from 6,000 to 6,200 and its 2026 target from 6,400 to 6,500, citing strong long-term trends in AI development [3] - The adoption rate of AI among businesses has been increasing, rising from 5.7% in Q4 of the previous year to 9.2% in Q2 of this year, significantly outpacing historical performance in the e-commerce sector [3] Group 4: Economic Indicators - The core PCE price index for May was reported at an annual rate of 2.68%, exceeding market expectations and reaching its highest level since February 2025 [6] - Despite a 0.1% decline in personal spending, which is the largest drop since the beginning of the year, inflationary pressures remain a concern [6] - The Federal Reserve's internal divisions regarding the timing and extent of potential interest rate cuts are increasing, influenced by differing views on the impact of tariffs on inflation and labor market resilience [6]

Core Viewpoint - Nvidia is on the verge of becoming the first company to reach a market capitalization of $4 trillion, following its previous milestone of being the first chip manufacturer to hit $1 trillion two years ago [1] Group 1: Market Performance - Nvidia's stock price has rebounded to historical highs after a significant drop earlier this year due to concerns about slowing investments in AI infrastructure [1] - Since its low in April, Nvidia's market capitalization has increased by 64%, reaching $3.78 trillion, surpassing Microsoft [1] Group 2: Customer Demand and Future Projections - There is a growing demand for Nvidia's latest AI accelerators, with investors believing there is substantial upside potential for the stock [4] - Loop Capital analyst Ananda Baruah raised Nvidia's target price from $175 to $250, suggesting a market cap of approximately $6 trillion, with expectations that AI spending will reach nearly $2 trillion annually by 2028 [4] Group 3: Competitive Landscape and Risks - Despite initial concerns about customer spending cuts due to cheaper alternatives like DeepSeek, major tech companies are increasing their capital expenditures, with an estimated $350 billion planned for the upcoming fiscal year [5] - Nvidia's chips are produced by TSMC, making the company susceptible to changes in U.S. trade policies, particularly those related to tariffs [5] - There are concerns that Nvidia's largest customers may alter their investment strategies, including developing their own chips to reduce reliance on Nvidia [6] Group 4: Valuation and Long-term Outlook - Nvidia's stock has a price-to-earnings ratio of 32 times expected earnings for the next 12 months, compared to the S&P 500's 22 times [6] - Despite potential volatility in performance and consumer spending, Nvidia is viewed as a significant beneficiary of long-term structural changes driven by AI technology [6]

Core Insights - The Jakarta-Bandung High-Speed Railway (HSR) has shown strong growth in passenger traffic since its opening on October 17, 2023, with over 10 million passengers transported by June 25, 2025 [2] - The railway significantly reduces travel time between Jakarta and Bandung from over 3 hours to just 46 minutes, enhancing the convenience for local residents [2] - Daily train operations have increased from 14 to 62 trains, with passenger capacity rising from over 8,400 to 37,000 seats, achieving a peak daily passenger volume of 25,000 and a seat occupancy rate of 99.64% [2] Company Operations - The collaboration between Chinese and Indonesian railway companies has focused on maintaining and operating the HSR effectively, improving transportation efficiency and service quality [2][4] - KCIC has implemented various passenger service enhancements, including online ticket sales, refund and rescheduling services, and the establishment of convenience stores at stations [3] - The HSR has maintained a high punctuality rate while accumulating over 463 million kilometers of safe operation [3] Future Plans - Future efforts will involve close collaboration between Chinese and Indonesian railway enterprises to monitor passenger demand and optimize train schedules, aiming to continuously improve service quality and transportation capacity [4]

Investment Rating - The report initiates coverage with a "Buy" rating for the company [3] Core Views - The company has completed its restructuring and is now empowered by its parent company, marking the beginning of a new chapter. It has transformed into a dual-driven healthcare industry group focusing on medical services and pharmaceutical manufacturing [1][19] - The company is actively developing a regional medical institution and is strategically positioning itself in the "silver economy" sector, with plans to enhance its healthcare services for the aging population [2][58] - The company has shown significant improvement in operational metrics, with a projected revenue of 3.799 billion yuan and a net profit of 115 million yuan for 2024, reflecting a year-on-year growth of 296.13% [1][5] Summary by Sections Company Overview - The company, formerly known as Gansu Duyiwei Biopharmaceutical Co., Ltd., was listed in 2008 and underwent a name change in 2014. After filing for bankruptcy in 2020, it successfully restructured in 2022 with the help of strategic investors [1][19] - The company has developed a "1+N" innovative service model, combining general hospitals with specialized branches, and is focusing on establishing a new type of elderly care model [1][16] Medical Services - As of May 2025, the company operates 4 tertiary hospitals and 13 secondary specialized hospitals, with a focus on creating regional medical centers [2][34] - The company is enhancing its service model by integrating elderly hospitals with care centers, targeting diseases prevalent among the elderly [34][61] Pharmaceutical Manufacturing - The pharmaceutical segment, led by the "Duyiwei" brand, has expanded its product matrix to include 82 varieties, with a revenue increase from 419 million yuan in 2019 to 753 million yuan in 2024 [2][63] - The company has made strategic acquisitions to broaden its business scope, forming a complete pharmaceutical industry chain [2][63] Financial Forecast and Valuation - The company is expected to achieve net profits of 167 million yuan, 202 million yuan, and 235 million yuan from 2025 to 2027, with corresponding PE ratios of 45.82, 37.83, and 32.63 [3][5] - Revenue projections for 2024 to 2027 indicate a stable growth trajectory, with expected annual growth rates of 7.8% to 10% [5][68]

Group 1 - The company, New Mile Health Technology Group Co., Ltd., announced that part of the shares held by shareholder Que Wenbin will be auctioned due to judicial proceedings [1][2] - The auction is scheduled to take place from July 21, 2025, 10:00 AM to July 22, 2025, 10:00 AM on the Taobao judicial auction platform [2] - Que Wenbin holds 44,172,769 shares, representing 22.73% of the company's total share capital, and this auction will not affect the company's control structure [3][4] Group 2 - As of the announcement date, Que Wenbin has a total of 599,692,230 shares that have been auctioned, which accounts for 17.70% of the company's total share capital [3][4] - Que Wenbin also holds 194,317,769 unrestricted circulating shares, which is 5.74% of the total shares, currently under freeze [4] - The company will monitor the changes in shareholding and disclose any significant information in a timely manner [4]